On December 12, 2025, Merus N.V. (MRUS) completed its acquisition by Genmab A/S and Genmab Holding II B.V. The 8-K filing disclosed a total aggregate consideration of $6.9 billion paid at $97.00 per common share, according to the Transaction Agreement dated September 29, 2025.

Genmab Holding II B.V. acquired 94.2 percent of Merus N.V.'s shares, resulting in a change of control, according to the filing. The Offer to Purchase was dated October 21, 2025, with the initial offer expiring on December 11, 2025. A Subsequent Offering Period will remain open until December 29, 2025.

Following the acquisition, Merus N.V. appointed new directors and executives. Jan van de Winkel, Ph.D., was appointed as director and Chief Executive Officer, replacing former CEO Sven (Bill) Ante Lundberg, M.D. New non-executive directors include Greg Mueller, Anthony Pagano, and Martine van Vugt, Ph.D., according to the filing.

The company disclosed Gross-Up Agreements for executives with an aggregate cap of $9,300,000 for potential excise taxes. Former directors and executives who ceased their roles include Peter Silverman, Mark Iwicki, Len Kanavy, Paolo Pucci, Victor Sandor, M.D.C.M., and Jason Haddock, according to the filing.